Current Position: Product Center
Anti-Mouse_PD1×VEGF hIgG1 Bispecific Antibody
Cat. No.
GM-88254MAB
Size
Quote
Related products
Product Info
Cat. No. & Size
Description
Data
Related products
Product Info

Cat. No:GM-88254MAB

Product:Anti-Mouse_PD1×VEGF hIgG1 Bispecific Antibody


Cat. No. & Size

GM-88254MAB-1mg / 1 mg

GM-88254MAB-5mg / 5 mg

GM-88254MAB-25mg / 5 mg * 5 vials

GM-88254MAB-50mg / 50 mg

GM-88254MAB-100mg / 50 mg * 2 vials



Description

Expression System

CHO

Aggregation

< 5% as determined by SEC-HPLC

Purity

> 95% as determined by SDS-PAGE

Endotoxin

< 1 EU/mg, determined by LAL gel clotting assay

Sterility

0.2 μm Filtered

Target

VEGF&PD1

Alternative Names

PD1: CD279

VEGF: VPF; MVCD1; L-VEGF

Source/Isotype

Monoclonal human IgG1 D265A, Kappa

Application

Flow cytometry; Block assay

Description

PD-1/VEGF Bispesific Antibody is a novel cancer immunotherapy drug that can target both PD-1 and VEGF. It blocks the interaction between PD-1 and PD-L1/PD-L2. The bispecific antibody can specifically bind to VEGFA and PD-1, selectively relieve the immune suppression caused by VEGFA and PD-1 in the body, and inhibit tumor-induced angiogenesis.

Formulation

20 mM Histidine, 150 mM NaCl, pH6.0



Data

image.png

image.png

image.png

image.png


Anti-Mouse_PD1×VEGF hIgG1 Bispecific Antibody
Cat. No.
GM-88254MAB
Size
Quote
Related products
Product Info
Cat. No. & Size
Description
Data
Related products
Product Info

Cat. No:GM-88254MAB

Product:Anti-Mouse_PD1×VEGF hIgG1 Bispecific Antibody


Cat. No. & Size

GM-88254MAB-1mg / 1 mg

GM-88254MAB-5mg / 5 mg

GM-88254MAB-25mg / 5 mg * 5 vials

GM-88254MAB-50mg / 50 mg

GM-88254MAB-100mg / 50 mg * 2 vials



Description

Expression System

CHO

Aggregation

< 5% as determined by SEC-HPLC

Purity

> 95% as determined by SDS-PAGE

Endotoxin

< 1 EU/mg, determined by LAL gel clotting assay

Sterility

0.2 μm Filtered

Target

VEGF&PD1

Alternative Names

PD1: CD279

VEGF: VPF; MVCD1; L-VEGF

Source/Isotype

Monoclonal human IgG1 D265A, Kappa

Application

Flow cytometry; Block assay

Description

PD-1/VEGF Bispesific Antibody is a novel cancer immunotherapy drug that can target both PD-1 and VEGF. It blocks the interaction between PD-1 and PD-L1/PD-L2. The bispecific antibody can specifically bind to VEGFA and PD-1, selectively relieve the immune suppression caused by VEGFA and PD-1 in the body, and inhibit tumor-induced angiogenesis.

Formulation

20 mM Histidine, 150 mM NaCl, pH6.0



Data

image.png

image.png

image.png

image.png


Message consultation
reset
submit
Message
Message consultation
reset
submit